

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6452219

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	WEINING LU	07/12/2017
	XUEPING FAN	07/12/2017
	DAVID J. SALANT	07/12/2017
RECEIVING PARTY DATA		
Name:	BOSTON MEDICAL CENTER CORPORATION	
Street Address:	ONE BOSTON MEDICAL CENTER PLACE	
City:	BOSTON	
State/Country:	MASSACHUSETTS	
Postal Code:	02218	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	15995286	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	MARIA.MARLEY@HGLAW.COM	
Correspondent Name:	HALEY GUILIANO LLP	
Address Line 1:	75 BROAD STREET, SUITE 1000	
Address Line 4:	NEW YORK, NEW YORK 10004	
ATTORNEY DOCKET NUMBER:	PCFC-0043-101	
NAME OF SUBMITTER:	MARIA E. MARLEY	
SIGNATURE:	/MARIA E. MARLEY/	
DATE SIGNED:	12/16/2020	
Total Attachments: 4		
source=PCFC-0043-101-Inv-BMCC-1#page1.tif		
source=PCFC-0043-101-Inv-BMCC-1#page2.tif		
source=PCFC-0043-101-Inv-BMCC-1#page3.tif		
source=PCFC-0043-101-Inv-BMCC-1#page4.tif		

ASSIGNMENT

WHEREAS, we, **Weining Lu, Xueping Fan, and David J. Salant** have invented one or more inventions described in a United States provisional patent application, entitled **RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND USES THEREOF**, which was filed on **June 2, 2017** as Application No. **62/514,242**;

WHEREAS, Boston Medical Center Corporation, (hereinafter "ASSIGNEE"), a Massachusetts Corporation, having principal offices at One Boston Medical Center Place, Massachusetts 02218, USA, desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention(s) as described in said application, together with our entire right, title and interest in and to said provisional patent application, including any patent application filed or to be filed in any country claiming the benefit thereof, and any continuations and divisions thereof, and any substitute applications therefor, and any Letters Patent which may issue thereon, and any reissues and revivals of the same, and including the right to claim priority under any applicable statute, treaty or convention based on said provisional patent application; said invention(s), application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by me had this assignment not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, all choses in action pertaining to the applications or Letters Patent including the right to sue for and collect damages and other recoveries for past infringement thereof, all rights to initiate proceedings before government and administrative bodies, and all files, records and other materials arising from the prosecution, exploitation, or defense of rights and registrations pertaining to the applications or Letters Patent. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution, reissue, divisional, continuation, or revival applications and preliminary or other statements and

the giving of testimony in any interference or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

IN TESTIMONY WHEREOF, we have hereunto set our hands and affixed our seal(s) the date set forth below.

This electronic signature is acceptable pursuant to MGL c.110G, § 1 et. seq., the Massachusetts Uniform Electronic Transaction Act (UETA).

Inventor's Signature: *Weining Lu*
Weining Lu (Jul 12, 2017)
Weining Lu
Date: Jul 12, 2017

This electronic signature is acceptable pursuant to MGL c.110G, § 1 et. seq., the Massachusetts Uniform Electronic Transaction Act (UETA).

Inventor's Signature: *Xueping Fan*
Xueping Fan Jul 12, 2017
Xueping Fan

Date: Jul 12, 2017

This electronic signature is acceptable pursuant to MGL c.110G, § 1 et. seq., the Massachusetts Uniform Electronic Transaction Act (UETA).

Inventor's Signature: David Salant
David Salant (Jul 12, 2017)
David J. Salant

Date: Jul 12, 2017